Orchestra BioMed Holdings Inc (OBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.00+7.91%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OBIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
1, 2026 (GLOBE NEWSWIRE), Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategi…
Stated in a supplied disclosure. Management reported: “1, 2026 (GLOBE NEWSWIRE), Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading medical device companies, today announced that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”), exceeding its previously announced target of 316 randomized patients.” “Clinical, Regulatory and Commercial Next Steps Orchestra BioMed and Medtronic intend to submit the BACKBEAT Trial’s primary endpoint results for consideration as a late-breaking clinical trial presentation at a major cardiovascular conference in the second quarter of 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
, referred to herein as “we,” “our,” “Orchestra BioMed,” and the “Company,” and from third - party sources indicated herein .
Stated in a supplied disclosure. Management reported: “, referred to herein as “we,” “our,” “Orchestra BioMed,” and the “Company,” and from third - party sources indicated herein .” “Such third - party information has not been independently verified .”
Such third - party information has not been independently verified .
Stated in a supplied disclosure. Management reported: “Such third - party information has not been independently verified .” “Orchestra BioMed makes no representation or warranty, expressed or implied, as to the accuracy or completeness of such information .”
Complete enrollment and follow-up in the BACKBEAT pivotal trial for AVIM Therapy, targeting primary endpoint data in Q2 2027 and subsequent regulatory submissions.
Generate revenue from milestone payments and royalties under strategic agreements, including $11 million expected proceeds in 2026.
Over the trailing year it converted 0.96x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
13 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.